MA31151B1 - Inhibiteurs de mapk/erk kinase - Google Patents

Inhibiteurs de mapk/erk kinase

Info

Publication number
MA31151B1
MA31151B1 MA32088A MA32088A MA31151B1 MA 31151 B1 MA31151 B1 MA 31151B1 MA 32088 A MA32088 A MA 32088A MA 32088 A MA32088 A MA 32088A MA 31151 B1 MA31151 B1 MA 31151B1
Authority
MA
Morocco
Prior art keywords
mapk
kinase inhibitors
compounds
erk kinase
manufacture
Prior art date
Application number
MA32088A
Other languages
Arabic (ar)
English (en)
Inventor
Qing Dong
Xianchang Gong
Stephen W Kaldor
Toufike Kanouni
Nicholas Scorah
Michael B Wallace
Feng Zhou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA31151B1 publication Critical patent/MA31151B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés de la formule suivante prévus pour une utilisation avec la mek (i), les variables étant telles que définies ici. De même, l'invention concerne des compositions pharmaceutiques, des nécessaires et des articles de fabrication comprenant ces composés. Des procédés et des intermédiaires utiles dans la fabrication des composés ; et des procédés d'utilisation desdits composés.
MA32088A 2006-12-20 2009-07-10 Inhibiteurs de mapk/erk kinase MA31151B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87091306P 2006-12-20 2006-12-20
PCT/US2007/087913 WO2008079814A2 (fr) 2006-12-20 2007-12-18 Inhibiteurs de mapk/erk kinase

Publications (1)

Publication Number Publication Date
MA31151B1 true MA31151B1 (fr) 2010-02-01

Family

ID=39462025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32088A MA31151B1 (fr) 2006-12-20 2009-07-10 Inhibiteurs de mapk/erk kinase

Country Status (35)

Country Link
US (4) US8030317B2 (fr)
EP (1) EP2125810B1 (fr)
JP (1) JP5513127B2 (fr)
KR (1) KR101488467B1 (fr)
CN (1) CN101679411B (fr)
AR (1) AR064640A1 (fr)
AU (1) AU2007337003B2 (fr)
BR (1) BRPI0720525B8 (fr)
CA (1) CA2673647C (fr)
CL (1) CL2007003742A1 (fr)
CO (1) CO6230984A2 (fr)
CR (1) CR10937A (fr)
DK (1) DK2125810T3 (fr)
EA (1) EA016312B1 (fr)
EC (1) ECSP099529A (fr)
ES (1) ES2430966T3 (fr)
GE (1) GEP20125511B (fr)
HR (1) HRP20130684T1 (fr)
IL (1) IL199362A (fr)
JO (1) JO2985B1 (fr)
MA (1) MA31151B1 (fr)
MX (1) MX2009006675A (fr)
MY (1) MY157871A (fr)
NO (1) NO342270B1 (fr)
NZ (1) NZ578310A (fr)
PE (1) PE20090071A1 (fr)
PL (1) PL2125810T3 (fr)
PT (1) PT2125810E (fr)
RS (1) RS52887B (fr)
SI (1) SI2125810T1 (fr)
TN (1) TN2009000249A1 (fr)
TW (1) TWI396538B (fr)
UA (1) UA98479C2 (fr)
WO (1) WO2008079814A2 (fr)
ZA (1) ZA200904682B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790649A1 (fr) * 2005-11-21 2007-05-30 Sanofi-Aventis Dérivés de pyrimidone substitués bicycliques
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
US7696218B2 (en) 2006-10-23 2010-04-13 Takeda San Diego, Inc. Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
JP5363350B2 (ja) * 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
WO2009064675A1 (fr) * 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Inhibiteurs de la mapk/erk kinase
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2010059503A2 (fr) * 2008-11-18 2010-05-27 Takeda Pharmaceutical Company Limited Procédés de fabrication de (r)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophénylamino)-8-méthylpyrido[2,3-d]pyrimidine-4,7(3h,8h)-dione et de ses intermédiaires
WO2012003338A1 (fr) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
TW201316991A (zh) 2011-06-03 2013-05-01 Millennium Pharm Inc Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
SI3321262T1 (sl) 2012-03-01 2021-04-30 Array Biopharma, Inc. Inhibitorji serin/treonin kinaze
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
US9868737B2 (en) * 2014-06-17 2018-01-16 Cisen Pharmaceutical Co., Ltd. Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitor
WO2016009306A1 (fr) * 2014-07-15 2016-01-21 Lupin Limited Composés hétérocyclyles utilisés comme inhibiteurs de mek
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
MX2019015431A (es) * 2017-06-23 2021-03-30 Cstone Pharmaceuticals Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117779203B (zh) * 2024-02-28 2024-05-31 西北工业大学 一种n-苄基-2-甲基-4-硝基苯胺单晶及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
HUP0105113A3 (en) 1999-01-13 2004-11-29 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
PL356802A1 (en) 2000-01-25 2004-07-12 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
UA76837C2 (uk) 2002-03-13 2006-09-15 Еррей Байофарма Інк. N3 алкіловані похідні бензімідазолу як інгібітори мек
ES2549159T3 (es) 2002-03-13 2015-10-23 Array Biopharma, Inc. Derivados de bencimidazol N3-alquilados como inhibidores de MEK
EP1636228B1 (fr) 2003-05-23 2008-10-22 AEterna Zentaris GmbH Nouvelles pyridopyrazines et leur utilisation en tant que modulateurs de kinases
AU2003277715A1 (en) 2003-07-03 2005-01-21 Sunghag Koo Ferment ginseng oil
WO2005009975A2 (fr) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazoles n-methyle-substitues
EP1651648A4 (fr) * 2003-07-29 2009-09-02 Irm Llc Composes et compositions utilises en tant qu'inhibiteurs des proteines kinases
DK1689233T3 (da) 2003-11-19 2012-10-15 Array Biopharma Inc Bicykliske inhibitorer af MEK
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
DE602005016718D1 (de) 2004-12-01 2009-10-29 Merck Serono Sa Coinsins Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
CA2657287A1 (fr) 2006-07-17 2008-01-24 Merck & Co., Inc. Composes de 1-hydroxy naphtyridine en tant qu'agents anti-vih
US7696218B2 (en) * 2006-10-23 2010-04-13 Takeda San Diego, Inc. Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
WO2008055842A1 (fr) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Dérivés de 6-phényl-pyrido [2,3-d] pyrimidine-7-one substitués utilisés comme inhibiteurs de la kinase et méthodes d'utilisation de ceux-ci
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2009064675A1 (fr) 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Inhibiteurs de la mapk/erk kinase
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2010059503A2 (fr) 2008-11-18 2010-05-27 Takeda Pharmaceutical Company Limited Procédés de fabrication de (r)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophénylamino)-8-méthylpyrido[2,3-d]pyrimidine-4,7(3h,8h)-dione et de ses intermédiaires

Also Published As

Publication number Publication date
WO2008079814A2 (fr) 2008-07-03
CR10937A (es) 2009-11-20
UA98479C2 (en) 2012-05-25
CA2673647C (fr) 2016-02-09
KR20090091353A (ko) 2009-08-27
US8470837B2 (en) 2013-06-25
EA200970605A1 (ru) 2009-12-30
NZ578310A (en) 2012-01-12
TW200835496A (en) 2008-09-01
JP5513127B2 (ja) 2014-06-04
US20080255160A1 (en) 2008-10-16
CO6230984A2 (es) 2010-12-20
NO20092692L (no) 2009-09-16
BRPI0720525B1 (pt) 2020-03-03
US20120202999A1 (en) 2012-08-09
AU2007337003A2 (en) 2009-07-30
BRPI0720525A2 (pt) 2014-01-07
ES2430966T3 (es) 2013-11-22
SI2125810T1 (sl) 2013-09-30
EP2125810A2 (fr) 2009-12-02
AU2007337003A1 (en) 2008-07-03
TWI396538B (zh) 2013-05-21
ECSP099529A (es) 2009-08-28
ZA200904682B (en) 2010-09-29
MX2009006675A (es) 2009-08-12
RS52887B (en) 2014-02-28
HRP20130684T1 (en) 2013-10-11
MY157871A (en) 2016-07-29
EP2125810B1 (fr) 2013-04-24
CN101679411A (zh) 2010-03-24
JO2985B1 (ar) 2016-09-05
IL199362A (en) 2013-07-31
US8293901B2 (en) 2012-10-23
CL2007003742A1 (es) 2008-06-13
NO342270B1 (no) 2018-04-30
TN2009000249A1 (en) 2010-10-18
US8030317B2 (en) 2011-10-04
DK2125810T3 (da) 2013-07-29
CA2673647A1 (fr) 2008-07-03
US20100130518A1 (en) 2010-05-27
PE20090071A1 (es) 2009-04-04
KR101488467B1 (ko) 2015-01-30
WO2008079814A3 (fr) 2008-09-04
CN101679411B (zh) 2013-04-17
GEP20125511B (en) 2012-05-10
PL2125810T3 (pl) 2013-09-30
AR064640A1 (es) 2009-04-15
BRPI0720525B8 (pt) 2021-05-25
US20110065733A1 (en) 2011-03-17
JP2010514680A (ja) 2010-05-06
EA016312B1 (ru) 2012-04-30
PT2125810E (pt) 2013-07-29
AU2007337003B2 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
MA31151B1 (fr) Inhibiteurs de mapk/erk kinase
MA32615B1 (fr) Inhibiteurs de cmet
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA31884B1 (fr) Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA32391B1 (fr) Activateurs de la glucokinase
WO2006105127A8 (fr) Inhibiteurs de l'hydroxysteroide deshydrogenase
MA32134B1 (fr) Composés hétérocycliques
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
ATE479687T1 (de) Kinaseinhibitoren
WO2006066109A3 (fr) Inhibiteurs des hydroxysteroides deshydrogenases
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
MA30655B1 (fr) Composes organiques.
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
WO2008115890A3 (fr) Inhibiteurs de mapk/erk kinase
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA29816B1 (fr) Composes de benzimidazole thiophene
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
CO5650217A2 (es) Composicion oral estable, antiplaca, que comprende un compuesto ester antibacteriano derivado de arginina
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
RS54416B1 (en) ROSTAFUROXIN FOR PHARMACOGENOMIC TREATMENT OF CARDIOVASCULAR STATES
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION